Table. Summary of Unadjusted Cohort Characteristics by Race.
| Variable | Cohorta | |||||
|---|---|---|---|---|---|---|
| SEER (n = 296 273) | VA (n = 3972) | RCT (n = 5854) | ||||
| White | Black | White | Black | White | Black | |
| All | 243 433 (82.1) | 52 840 (17.8) | 2459 (61.9) | 1513 (38.1) | 4725 (80.7) | 1129 (19.3) |
| Follow-up, median (IQR), mob | 76 (49-105) | 70 (45-100) | 98 (61-145) | 94 (55-142) | 105 (71-132) | 101 (60-131) |
| Age, median (IQR), y | 65 (59-71) | 62 (56-69) | 64 (60-68) | 61 (56-65) | 71 (66-74) | 69 (64-73) |
| Gleason biopsy scorec | ||||||
| ≤6 | 115 709 (47.5) | 23 304 (44.1) | 1214 (49.4) | 724 (47.9) | 1926 (40.8) | 494 (43.8) |
| 7 | 95 810 (39.4) | 22 515 (42.6) | 896 (36.4) | 600 (39.7) | 1978 (41.9) | 424 (37.6) |
| 8 | 18 440 (7.6) | 4498 (8.5) | 248 (10.1) | 142 (9.4) | 512 (10.8) | 140 (12.4) |
| 9-10 | 13 474 (5.5) | 2523 (4.8) | 101 (4.1) | 47 (3.1) | 309 (6.5) | 71 (6.3) |
| T stage | ||||||
| T1-T2a | 109 467 (45.0) | 28 634 (54.2) | 2040 (83.0) | 1339 (88.5) | 2306 (48.8) | 619 (54.8) |
| T2b-T2c | 108 214 (44.5) | 19 878 (37.6) | 398 (16.2) | 171 (11.3) | 1393 (29.5) | 307 (27.2) |
| T3-T4 | 25 752 (10.6) | 4328 (8.2) | 21 (0.9) | 3 (0.2) | 1026 (21.7) | 203 (18.0) |
| N stage | ||||||
| N0 | 237 646 (97.6) | 51 727 (97.9) | 2459 (100) | 1513 (100) | 2802 (59.3) | 657 (58.2) |
| N1-N2 | 5787 (2.4) | 1113 (2.1) | 0 | 0 | 59 (1.2) | 12 (1.1) |
| NX | 0 | 0 | 0 | 0 | 1864 (39.4) | 460 (40.7) |
| Pretreatment PSA level, ng/mL | ||||||
| Median (IQR) | 6.0 (4.5-8.9) | 6.6 (4.8-10.8) | 6.2 (4.6-9.2) | 7.0 (4.9-10.7) | 11.5 (7.2-17.7) | 13.7 (7.9-22.2) |
| <10 | 194 149 (79.8) | 38 086 (72.1) | 1944 (79.1) | 1071 (70.8) | 1991 (42.1) | 404 (35.8) |
| ≥10 to 19 | 34 055 (14.0) | 9278 (17.6) | 392 (15.9) | 319 (21.1) | 1599 (33.8) | 347 (30.7) |
| ≥20 | 15 229 (6.3) | 5476 (10.4) | 123 (5.0) | 123 (8.1) | 1135 (24.0) | 378 (33.5) |
| Risk groupd | ||||||
| Low | 54 305 (22.3) | 11 574 (21.9) | 868 (35.3) | 474 (31.3) | 524 (11.1) | 130 (11.5) |
| Intermediate | 130 387 (53.6) | 27 693 (52.4) | 1134 (46.1) | 750 (49.6) | 2115 (44.8) | 444 (39.3) |
| High | 52 954 (21.8) | 12 460 (23.6) | 457 (18.6) | 289 (19.1) | 2027 (42.9) | 543 (48.1) |
| Node positive | 5787 (2.4) | 1113 (2.1) | 0 | 0 | 59 (1.2) | 12 (1.1) |
Abbreviations: IQR, interquartile range; PSA, prostate specific antigen; RCT, randomized control trial; SEER, Surveillance, Epidemiology, and End Results; VA, Veterans Affairs.
SI conversion factor: To convert PSA to micrograms per liter, multiply by 0.001.
Cohorts are derived from the SEER database, shared equal-access VA regional hospital cohort, and Radiation Therapy Oncology Group RCTs. Unless otherwise indicated, data are expressed as number (percentage) of patients. Percentages have been rounded and may not total 100.
Follow-up for the SEER cohort began at time of diagnosis, whereas follow-up for the VA and RCT cohorts began at time of radical treatment.
Higher scores indicate higher grade.
Defined per the National Comprehensive Cancer Network.